Travere Therapeutics Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Travere Therapeutics stock.
View analyst ratings for Travere Therapeutics or view top-rated stocks.

Wall Street analysts have given Travere Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Travere Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Travere Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Travere Therapeutics.

Travere Therapeutics, Inc. (NASDAQ:TVTX) released its quarterly earnings data on Monday, March, 1st. The company reported ($2.37) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.43) by $1.94. Travere Therapeutics had a negative net margin of 40.24% and a negative trailing twelve-month return on equity of 29.27%.
View Travere Therapeutics' earnings history.

Travere Therapeutics issued an update on its fourth quarter 2020 Pre-Market earnings guidance on Monday, January, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $51-51 million, compared to the consensus revenue estimate of $51.33 million.

3 equities research analysts have issued twelve-month target prices for Travere Therapeutics' shares. Their forecasts range from $43.00 to $51.00. On average, they anticipate Travere Therapeutics' stock price to reach $47.00 in the next twelve months. This suggests a possible upside of 71.5% from the stock's current price.
View analysts' price targets for Travere Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Travere Therapeutics include Atea Pharmaceuticals (AVIR), Maravai LifeSciences (MRVI), TG Therapeutics (TGTX), Perrigo (PRGO), Blueprint Medicines (BPMC), Turning Point Therapeutics (TPTX), Galapagos (GLPG), Emergent BioSolutions (EBS), Biohaven Pharmaceutical (BHVN), Sage Therapeutics (SAGE), Eidos Therapeutics (EIDX), Arena Pharmaceuticals (ARNA), ChemoCentryx (CCXI), Reata Pharmaceuticals (RETA) and Hutchison China MediTech (HCM).
View all of TVTX's competitors.

Travere Therapeutics trades on the NASDAQ under the ticker symbol "TVTX."

Travere Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.45%), Janus Henderson Group PLC (8.00%), The Manufacturers Life Insurance Company (4.28%), Renaissance Technologies LLC (3.65%), Avoro Capital Advisors LLC (3.53%) and Dimensional Fund Advisors LP (2.33%). Company insiders that own Travere Therapeutics stock include Elizabeth E Reed, Eric M Dube, Laura Clague, Noah L Rosenberg and William E Rote.
View institutional ownership trends for Travere Therapeutics.

TVTX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Janus Henderson Group PLC, The Manufacturers Life Insurance Company , Renaissance Technologies LLC, Avoro Capital Advisors LLC, Dimensional Fund Advisors LP, Nuveen Asset Management LLC, and Scopia Capital Management LP.
View insider buying and selling activity for Travere Therapeutics or or view top insider-buying stocks.

Shares of TVTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TVTX stock can currently be purchased for approximately $27.41.

Travere Therapeutics has a market capitalization of $1.40 billion and generates $175.34 million in revenue each year. The company earns $-146,430,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis.

The official website for Travere Therapeutics is www.retrophin.com.

Travere Therapeutics is headquartered at 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130.

Travere Therapeutics' mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The company can be reached via phone at (888) 969-7879 or via email at [email protected]